

Cancer Market Outlook to 2015: Competitive Landscape, Market Size, Pipeline Analysis, and Growth Opportunities

Introduction

The report provides epidemiological analysis, and forecasts prevalence of the major cancer indications turning 2009-2015, including lung, breast, colorectal, and ovarian cancer markets. Also included are detailed analyses of the clinically differentiated products in the cancer pipeline by indication, and sales forecasts for key R&D pipeline products in the global cancer market.

Scope

- Forecasts of major cancer products introduced during 2009-2015, across major indications and classes of treatment.
- Strategic & growth analysis of leading pharmaceutical companies, including their sales by drug class, currently marketed products, and new products in R&D.
- Detailed analysis of major classes of cancer treatments, including antineoplastics and cytotoxic hormone therapies.
- Analysis of the clinically differentiated products in cancer pipeline by indication, and sales forecasts of key R&D pipeline products.

Research and analysis highlights

Antineoplastics formed the leading drug class for cancer treatment. While competition is strong within the antineoplastic market, four drugs dominated the global antineoplastics market - Roche's Avastin (bevacizumab), MabThera (rituximab), and Herceptin (trastuzumab), and Novartis's Glivec (imatinib).

Cytostatic hormone therapies formed the other major drug class in the global cancer market, which was led by cytostatic aromatase inhibitors, cytostatic gonad hormone analogs and cytostatic anti-androgens. Arimidex and Femara remained the leading drugs in cytostatic hormone therapy registering Y-o-Y growth of around 3% and 15% respectively in 2009.

In 2009, monoclonal antibodies (mAbs) accounted for the majority of sales, achieving almost 30% share among the top 10 brands in the global cancer market. This was largely driven by the commercial success of the mAb brands: MabThera, Avastin, and Herceptin.

Key reasons to purchase this research

- Develop insight into patient potential with coverage of cancer indications, 7 major markets & the top 10 players
- Understand how recent events are affecting the performance of major products & how their marketers are confronting competitive changes
- Gain up-to-date competitive intelligence across the cancer indications and understand the major issues affecting key pharmaceutical/biotech players
- Understand which indications have potential to provide franchise growth & how pharmaceutical companies are attempting to exploit these opportunities
- Compare pharmaceutical marketers franchises across indications & understand how market share of leading companies will change over the next 6 years

Table of Contents

About Business Insights 2

Disclaimer 2

Executive summary 15

Overview and epidemiology of cancer indications 15

Global market analysis 16

Pipeline analysis 16

Competitive landscape 17

Chapter 1 Scope and methodology 19

Scope 19

Key cancer indications covered in this report 19

Methodology 20

Chapter 2 Overview and epidemiology of cancer indications 21

Summary 21

Introduction 22

Overview 22

Cancer risk factors 22

Lung cancer 24

Overview 24

Diagnosis, treatment and management 25

Epidemiology 26

NSCLC 26

SCLC 27

Forecast epidemiology 28

NSCLC 28

SCLC 29

Colorectal cancer 31

Overview 31

Diagnosis, treatment and management 31

Epidemiology 32

Forecast epidemiology 33

Breast cancer 35

Overview 35

Diagnosis, treatment and management 35

Epidemiology 36

Forecast epidemiology 37

Ovarian cancer 39

Overview 39

Diagnosis, treatment and management 40

Epidemiology 40

Forecast epidemiology 41

Uterine and cervical cancer 43

Overview 43

Diagnosis, treatment and management 43

Epidemiology 44

Forecast epidemiology 44

Leukemia 46

Overview 46

Diagnosis, treatment and management 47

Epidemiology 47

Forecast epidemiology 48

Prostate cancer 50

Overview 50

Diagnosis, treatment and management 50

Epidemiology 51

Forecast epidemiology 52

Pancreatic cancer 54

Overview 54
Diagnosis, treatment and management 54
Epidemiology 55
Forecast epidemiology 55
Lymphomas 57
Overview 57
Diagnosis, treatment and management 57
Epidemiology 58
Forecast epidemiology 59
Head and neck cancer 61
Overview 61
Diagnosis, treatment and management 62
Epidemiology 63
Forecast epidemiology 63
Chapter 3 Global market analysis 65
Summary 65
Introduction 65
Market analysis by country 66
Market analysis by drug class 68
Leading brand dynamics 69
Avastin (bevacizumab) – Roche 70
MabThera (rituximab) – Roche 72
Herceptin (trastuzumab) – Roche 73
Glivec/Gleevec (imatinib) – Novartis 74
Taxotere (docetaxel) – Sanofi-Aventis 75
Leading brands by type of cancer 76
Key recent events in the cancer market 79
Antineoplastics 82
Competitive dynamics of antineoplastics 82

Leading antineoplastic brands 84

Antineoplastic mAb market analysis 85

Market dynamics 85

Key brands analysis 85

Antineoplastic protein kinase inhibitors 87

Market dynamics 87

Key brands analysis 87

Vinca alkaloid market analysis 88

Market dynamics 88

Key brands analysis 88

Anti-metabolites 88

Market dynamics 88

Key brands analysis 89

Platinum compounds 89

Market dynamics 89

Key brands analysis 89

Antineoplastic sales forecast 90

Cytostatic hormonal therapies 91

Competitive dynamics of cytostatic hormonal therapies 91

Leading brands of cytostatic hormonal therapies 92

Cytostatic aromatase inhibitors market analysis 93

Market dynamics 93

Key brands analysis 94

Cytostatic gonadotrophin-releasing hormone analog market analysis 95

Market dynamics 95

Key brands analysis 95

Cytostatic anti-androgens 96

Market dynamics 96

Key brands analysis 96

Cytostatic hormonal therapy sales forecast 97

Global cancer market sales forecast 98

Generic cancer market 99

Chapter 4 Pipeline analysis 103

Summary 103

Introduction 104

Key trends in R&D 104

Targeted therapies are changing the treatment regimen of cancer 104

Cancer vaccines enhance the body's immune response 105

Pricing is becoming a major issue for cancer patients 105

Combination treatments are becoming the treatment of choice 106

Oncology pipeline 107

Leading drugs in development 108

Recently approved/marketed drugs 110

Afinitor (everolimus) – Novartis 110

Arzerra (ofatumumab) – GSK/Genmab 111

Votrient (pazopanib) – GSK 114

Provenge (sipuleucel-T) – Dendreon 116

Trastuzumab-DM1 (T-DM1) – Roche 117

Phase III compounds 120

Stimuvax (emepepimut- S) – Merck Serono 120

Ipilimumab (MDX-010) – Bristol Myers Squibb (BMS) 122

Omnitarg (pertuzumab) – Roche 124

Abiraterone – Johnson & Johnson (J&J) 126

BSI-201(iniparib) – Sanofi-Aventis 128

Pipeline forecast of leading drugs in development 130

Factors affecting forecasts 130

Chapter 5 Competitive landscape 131

Summary 131

Introduction 132

Sales performance of leading players 132

Roche 134

Sales focus by drug class 135

Regional sales distribution 135

Marketed product portfolio 136

Pipeline analysis 138

Strategic and growth analysis 140

Drivers of growth 140

Resistors of growth 141

Novartis 142

Sales focus by drug class 142

Regional sales distribution 143

Marketed product portfolio 144

Pipeline analysis 145

Strategic and growth analysis 147

Drivers of growth 147

Resistors of growth 147

Sanofi-Aventis 148

Sales focus by drug class 148

Regional sales distribution 149

Marketed product portfolio 150

Pipeline analysis 151

Strategic and growth analysis 153

Drivers of growth 153

Resistors of growth 154

AstraZeneca 154

Sales focus by drug class 154

Regional sales distribution 155

Marketed products portfolio	156
Pipeline analysis	157
Strategic and growth analysis	158
Drivers of growth	158
Resistors of growth	159
Eli Lilly	160
Sales focus by drug class	160
Regional sales distribution	160
Marketed products portfolio	161
Pipeline analysis	162
Strategic and growth analysis	163
Drivers of growth	163
Resistors of growth	164
Competitive positioning of top true generic players in the cancer market	165
Appendix	167
IMS data	167
Antineoplastic and immunomodulating agents	167
L1: Antineoplastics	167
L2: Cytostatic hormone therapy	167
Forecast factors	167
Epidemiology forecast:	167
Market forecast:	167
Glossary	168
Abbreviations	168
Trial expansions	171
Table of figures	
Figure 1: Treatment of lung cancer by stage	25
Figure 2: Types of breast cancers	35

- Figure 3: Types of leukemia 46
- Figure 4: Chemotherapy options for Hodgkin's disease 58
- Figure 5: Head and neck cancers and their risk factors 62
- Figure 6: 7MM cancer market share by region (%), 2009 67
- Figure 7: Relative positions of the 7MM in the global cancer market, 2009 68
- Figure 8: Current pharmacological treatment options for cancer 107
- Figure 9: Oncology pipeline by indication and stage of development, 2010 108
- Figure 10: Key drugs in late-stage development or that have been recently launched 109
- Figure 11: Contribution of the top 10 players to growth of the global cancer market, 2008–09 134
- Figure 12: Roche's cancer sales by drug class (\$m), 2009 135
- Figure 13: Novartis' cancer sales by drug class (\$m), 2009 143
- Figure 14: Sanofi-Aventis' cancer sales by drug class (\$m), 2009 149
- Figure 15: AstraZeneca's cancer sales by drug class (\$m), 2009 155
- Figure 16: Competitive positioning of the top 10 true generic players in the 7MM, 2009 166

Table of tables

- Table 1: Estimated prevalence of NSCLC across the seven major markets, 2009 27
- Table 2: Estimated prevalence of SCLC across the seven major markets, 2009 28
- Table 3: Forecast epidemiology of NSCLC across the seven major markets, 2009-15 29
- Table 4: Forecast epidemiology of SCLC across the seven major markets, 2009-15 30
- Table 5: Estimated prevalence of colorectal cancer across the seven major markets, 2009 33
- Table 6: Forecast epidemiology of colorectal cancer across the seven major markets, 2009-15 34
- Table 7: Estimated prevalence of breast cancer across the seven major markets, 2009 37
- Table 8: Forecast epidemiology of breast cancer across the seven major markets, 2009-15 38

Table 9: Estimated prevalence of ovarian cancer across the seven major markets, 2009
41

Table 10: Forecast epidemiology of ovarian cancer across the seven major markets,
2009-15 42

Table 11: Estimated prevalence of uterine and cervical cancer across the seven major
markets, 2009 44

Table 12: Forecast epidemiology of uterine and cervical cancer across the seven major
markets, 2009-15 45

Table 13: Estimated prevalence of leukaemia across the seven major markets, 2009 48

Table 14: Forecast epidemiology of leukemia across the seven major markets, 2009-15
49

Table 15: Estimated prevalence of prostate cancer across the seven major markets, 2009
52

Table 16: Forecast epidemiology of prostate cancer across the seven major markets,
2009-15 53

Table 17: Estimated prevalence of pancreatic cancer across the seven major markets,
2009 55

Table 18: Forecast epidemiology of pancreatic cancer across the seven major markets,
2009-15 56

Table 19: Estimated prevalence of lymphomas across the seven major markets, 2009 59

Table 20: Forecast epidemiology of lymphomas across the seven major markets, 2009-
15 60

Table 21: Estimated prevalence of head and neck cancers across the seven major
markets, 2009 63

Table 22: Forecast epidemiology of head and neck cancers across the seven major
markets, 2009-15 64

Table 23: Global cancer market by geography (\$m), 2009 66

Table 24: Breakdown of the global cancer market by drug class(\$m), 2009 69

Table 25: Leading brands in the global cancer market (\$m), 2009 70

- Table 26: Leading brands in breast cancer (\$m), 2009 77
- Table 27: Leading brands in colon cancer (\$m), 2009 77
- Table 28: Leading brands in prostate cancer (\$m), 2009 78
- Table 29: Leading brands in lung cancer (\$m), 2009 78
- Table 30: Breakdown of the global antineoplastic market by drug class (\$m), 2009 83
- Table 31: Leading brands in global antineoplastics market (\$m), 2009 84
- Table 32: Antineoplastic sales forecast (\$m), 2009-15 90
- Table 33: Breakdown of the global cytostatic hormonal therapies by drug class (\$m), 2009 92
- Table 34: Leading brands in global cytostatic hormonal therapies market (\$m), 2009 93
- Table 35: Cytostatic hormonal therapy sales forecast (\$m), 2009-15 98
- Table 36: Global cancer market sales forecast (\$m), 2009–15 99
- Table 37: Classification of the generic cancer market in the 7MM (\$m), 2009 100

